Item 7.01 Regulation FD Disclosure.

Beginning on March 8, 2022, members of management of VYNE Therapeutics Inc. (the "Company") will begin using the updated investor presentation found on the Company's website in connection with investor meetings and industry conferences. The presentation has been updated to include the preclinical data for the Company's lead BET inhibitor, VYN201, in a human skin model of vitiligo, as announced by the Company on March 7, 2022. In addition, the presentation reflects an updated timeline for the Company's receipt of top line results from its Phase 2a study evaluating the safety and efficacy of FMX114 for the treatment of mild-to-moderate atopic dermatitis. The Company expects to report Phase 2a top line results in the second quarter of 2022, versus prior expectations of the first quarter 2022, primarily due to COVID-19-related enrollment delays in Australia, where the study is being conducted. The updated investor presentation can be found in the "Events & Presentations" section of the Company's website.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

© Edgar Online, source Glimpses